Compare Linde PLC (LIN) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Organon & Co. Common Stock — how do they compare? Linde PLC trades at $494.86 (market cap $226.85B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Linde PLC is far larger — about 62.7× Organon & Co. Common Stock's market cap, and Linde PLC pays the higher dividend (1.3%). Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 89 Days and Organon & Co. Common Stock for 0 Days on average.
| LIN | OGN | |
|---|---|---|
Market Cap | $226.85B | $3.62B |
Volume | 1,386,042 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $13.81 |
52-Week Low | $389.38 | $5.70 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $249.97B | $11.04B |
Dividend Yield | 1.3% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $487.35, up 0.75% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 20.43% net margins, and robust cash flow generation. Analyst consensus is overwhelmingly bullish with a $558.91 price target, representing 15% upside potential. Recent Q2 2026 results exceeded expectations with $4.50 EPS, driven by volume and pricing growth across key markets including electronics.
LIN offers quality exposure to industrial gases with AI chip contract potential, though elevated P/E of 31.75 requires sustained growth. Risks include margin pressure from higher CAPEX and sector-wide competition. The stock presents a compelling opportunity for investors seeking stable industrial exposure with growth catalysts, supported by strong institutional backing and consistent dividend payments.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
